Meropenem/vaborbactam Activity In Vitro: A New Option for Klebsiella Pneumoniae Carbapenemase (KPC)-Producing Klebsiella Pneumoniae Treatment

References

• Pitout JDD , NordmannP, PoirelL. Carbapenamase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob. Agents Chemother.59(10), 5873–5884 (2015).
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control . Surveillance of antimicrobial resistance in Europe 2018. www.ecdc.europa.eu/sites/default/files/documents/surveillance-antimicrobial-resistance-Europe-2018.pdf
   Google Scholar
• Osservatorio Epidemiologico Regione Puglia . Sorveglianza epidemiologica degli isolati da emocoltura di Enterobatteri resistenti ai carbapenemi (CRE) A.O.U.C. Policlinico di Bari Report Anno. Regione Puglia Report Anno (2019). https://www.sanita.puglia.it/web/oer
   Google Scholar
• Giani T , AntonelliA, CaltagironeMet al. Evolving beta-lactamase epidemiology in Enterobacteriaceae from Italian nationwide surveillance, October 2013: KPC-carbapenemase spreading among outpatients. Euro. Surveill.22(31), 30583 (2017).
   PubMedGoogle Scholar
• Conte V , MonacoM, GianiTet al. Molecular epidemiology of KPC-producing Klebsiella pneumoniae from invasive infections in Italy: increasing diversity with predominance of the ST512 clade II sublineage. J. Antimicrob. Chemother.71(12), 3386–3391 (2016).
   PubMed Web of Science ®Google Scholar
• Karaiskos I , GalaniI, SouliM, GiamarellouH. Novel β-lactams-β-lactamase inhibitor combinations: expectation for the treatment of carbapenem-resistant Gram-negative pathogens. Expert Opin. Drug Metab. Toxicol.15(2), 133–149 (2019).
   PubMed Web of Science ®Google Scholar
• Alraddadi BM , SaeediM, QutubM, AlshukairiA, HassanienA, WaliG. Efficacy of ceftazidime/avibactam in the treatment of infections due to carbapenem resistant Enterobacteriaceae. BMC Infect. Dis.19(1), 772–777 (2019).
   PubMed Web of Science ®Google Scholar
• Camargo JF , SimkinsJ, BeduschiTet al. Successful treatment of carbapenemase-producing pandrug-resistant Klebsiella pneumoniae bacteremia. Antimicrob. Agents Chemother.59(10), 5903–5908 (2015).
   PubMed Web of Science ®Google Scholar
• Cho JC , ZmarlckaMT, ShaeerKMet al. Meropenem/vaborbactam, the first carbapenem/beta lactamase inhibitor combination. Ann. Pharmacother.52(8), 769–779 (2018).
   PubMed Web of Science ®Google Scholar
• Dhillon S . Meropenem/vaborbactam: a review in complicated urinary tract infections. Drugs78(12), 1259–1270 (2018).
   PubMed Web of Science ®Google Scholar
• Lomovskaya O , SunD, Rubio-AparicioDet al. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob. Agents Chemother.61(11), 1443–17 (2017).
   PubMed Web of Science ®Google Scholar
• Castanheira M , RhombergPR, FlammRK, JonesRN. Effect of beta lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae. Antimicrob. Agents Chemother.60(9), 5454–5458 (2016).
   PubMed Web of Science ®Google Scholar
• Ehmann DE , JahicH, RossPLet al. Kinetics of avibactam inhibition against class A, C, and D β-lactamases. J. Biol. Chem.288(39), 27960–27971 (2013).
   PubMed Web of Science ®Google Scholar
• Onorato L , DiCaprio G, SignorielloSet al. Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: a meta-analysis. Int. J. Antimicrob. Agents54(6), 735–740 (2019).
   PubMed Web of Science ®Google Scholar
• Wang Y , WangJ, WangRet al. Resistance to ceftazidime-avibactam and underlying mechanisms. J. Glob. Antimicrob. Resist.22, 18–27 (2020).
   PubMed Web of Science ®Google Scholar
• Göttig S , FrankD, MungoEet al. Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniaein vivo. J. Antimicrob. Chemother.74(11), 3211–3216 (2019).
   PubMed Web of Science ®Google Scholar
• The European Committee on Antimicrobial Susceptibility Testing . Breakpoint tables for interpretation of MICs and zone diameters. www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_10.0_Breakpoint_Tables.pdf
   Google Scholar
• Wagner BA , DargatzDA, MorleyPSet al. Analysis methods for evaluating bacterial antimicrobial resistance outcomes. Am. J. Vet. Res.64(12), 1570–1579 (2003).
   PubMed Web of Science ®Google Scholar
• Wong D , van DuinD. Novel beta-lactamase inhibitors: unlocking their potential in therapy. Drugs77(6), 615–628 (2017).
   PubMed Web of Science ®Google Scholar
• Kazmierczak KM , de JongeBLM, StoneGGet al. In vitro activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012–15. J. Antimicrob. Chemother.73(10), 2782–2788 (2018).
   PubMed Web of Science ®Google Scholar
• Hackel MA , LomovskayaO, DudleyMNet al. In vitro activity of meropenem-vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae. Antimicrob. Agents Chemother.62(1), 1–10 (2018).
   Web of Science ®Google Scholar
• Petty LA , HenigO, PatelTS, PogueJM, KayeKS. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae. Infect. Drug Resist.11, 1461–1472 (2018).
   PubMed Web of Science ®Google Scholar
• Athans V , NeunerEA, HassounHet al. Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-resistant Klebsiella pneumoniae bacteremia and abscess in a liver transplant recipient. Antimicrob. Agents Chemother.63(1), 1551–1518 (2019).
   PubMed Web of Science ®Google Scholar
• Ackley R , RoshdyD, MeredithJet al. Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections. Antimicrob. Agents Chemother.64(5), e02313–e02319 (2020).
   PubMed Web of Science ®Google Scholar
• Pogue JM , BonomoRA, KayeKS. Ceftazidime/avibactam, meropenem/vaborbactam, or both? Clinical and formulary considerations. Clin. Infect. Dis.68(3), 519–524 (2019).
   PubMed Web of Science ®Google Scholar